Once multiple sclerosis (MS) is diagnosed (see presentation), periodic assessment of disease severity is important both for tracking disease progression (and establishing prognosis) and for monitoring ...

A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation ...

Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...

A previously "hidden" subtype of Multiple Sclerosis (MS)—a condition that affects the brain and spinal cord—has been uncovered. The distinct subtype exhibits "significant cognitive deficits with ...

—A retrospective analysis found that patients with RRMS who experience cognitive decline do so independent of EDSS worsening, but more overall events were found using multiple cognitive tests than ...

"The findings suggest that the central vein sign can be used by neurologists to help distinguish MS from other radiological mimics. The results of the study suggest abbreviated methods of assessing ...

Presentation raises questions about EBV timing. Dalia Rotstein, MD, of the University of Toronto, discussed the findings and their implications in an oral presentation at the Amer ...

When an insurance denial blocks guest writer Denise Schnieders from getting an MS disease activity test, she decides to fight back.

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...